Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A2 | P23975 | 4/20 | 0.50 |
| ▸ | SLC6A4 | P31645 | 3/20 | 0.50 |
| ▸ | CETP | P11597 | 15/20 | 0.49 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL994018 | 0.92 | SLC6A2 (0.58) | SLC6A2SLC6A4CETPSLC6A3 | |
| SCHEMBL992460 | 0.89 | CETP (0.51) | SLC6A2SLC6A4CETPSLC6A3 | |
| SCHEMBL993382 | 0.82 | CETP (0.49) | SLC6A2SLC6A4CETP | |
| SCHEMBL993642 | 0.82 | CETP (0.63) | CETP | |
| SCHEMBL994090 | 0.81 | CETP (0.60) | SLC6A2SLC6A4CETP | |
| SCHEMBL993039 | 0.80 | SLC6A2 (0.44) | SLC6A2SLC6A4CETP | |
| SCHEMBL7039973 | 0.80 | CETP (0.47) | CETP | |
| SCHEMBL992166 | 0.80 | CETP (0.58) | CETP | |
| SCHEMBL1898984 | 0.80 | CETP (0.44) | SLC6A2SLC6A4CETP | |
| SCHEMBL993326 | 0.79 | SLC6A2 (0.49) | SLC6A2SLC6A4SLC6A3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 79 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6787570-B2 | ADMINISTERING AN AROMATIC OR HETEROAROMATIC SUBSTITUTED TERTIARYAMINE COMPOUND TO TREAT ATHEROSCLEROSIS, DYSLIPIDEMIA, AND OTHER CORONARY ARTERY DISEASES | PFIZER, INC. | 2004-09-07 | — | — | US | claimed |
| US-20030191306-A1 | Substituted N-Aliphatic-N-Aromatictertiary-Heteroalkylamines useful for inhibiting cholesteryl ester transfer protein activity | G.D. SEARLE & CO. (US) | 2003-10-09 | — | — | US | claimed |
| US-20010018446-A1 | Substituted N-Aliphatic-N-Aromatictertiary-Heteroalkylamines useful for inhibiting cholesteryl ester transfer protein activity | G.D. SEARLE & CO. (US) | 2001-08-30 | — | — | US | claimed |
| US-20160374945-A1 | PHARMACEUTICAL COMPOSITIONS OF DISPERSIONS OF DRUG AND NEUTRAL POLYMERS | BEND RESEARCH, INC. (US) | 2016-12-29 | — | — | US | disclosed |
| US-9468604-B2 | Pharmaceutical compositions of dispersions of drug and neutral polymers | BEND RESEARCH, INC. (US) | 2016-10-18 | — | — | US | disclosed |
| US-20140210117-A1 | PHARMACEUTICAL COMPOSITIONS OF DISPERSIONS OF DRUG AND NEUTRAL POLYMERS | BEND RESEARCH, INC. (US) | 2014-07-31 | — | — | US | disclosed |
| US-8703199-B2 | Pharmaceutical compositions of adsorbates of amorphous drug | BEND RESEARCH, INC. (US) | 2014-04-22 | — | — | US | disclosed |
| US-8703196-B2 | Pharmaceutical compositions of dispersions of amorphous drugs mixed with polymers | BEND RESEARCH, INC. (US) | 2014-04-22 | — | — | US | disclosed |
| US-8389011-B2 | Pharmaceutical compositions of cholesteryl ester transfer protein inhibitors | BEND RESEARCH, INC. (US) | 2013-03-05 | — | — | US | disclosed |
| US-8389006-B2 | Pharmaceutical compositions of adsorbates of amorphous drug | BEND RESEARCH, INC. (US) | 2013-03-05 | — | — | US | disclosed |
| US-20120295988-A1 | Pharmaceutical Compositions of Dispersions of Amorphous Drugs Mixed with Polymers | BEND RESEARCH, INC. | 2012-11-22 | — | — | US | disclosed |
| US-20030054038-A1 | Pharmaceutical compositions of drugs and neutralized acidic polymers | BEND RESEARCH, INC. | 2003-03-20 | — | — | US | disclosed |
| US-20030054037-A1 | Pharmaceutical compositions of adsorbates of amorphous drug | BEND RESEARCH, INC. | 2003-03-20 | — | — | US | disclosed |
| US-20030022944-A1 | Self-emulsifying formulations of cholesteryl ester transfer protein inhibitors | PFIZER INC. | 2003-01-30 | — | — | US | disclosed |
| WO-2003000235-A1 | PHARMACEUTICAL COMPOSITIONS OF DISPERSIONS OF DRUGS AND NEUTRAL POLYMERS | PFIZER PRODUCTS INC. (US) | 2003-01-03 | — | — | WO | disclosed |
| WO-2003000294-A1 | PHARMACEUTICAL COMPOSITIONS CONTAINING A SOLID DISPERSION OF A POORLY-SOLUBLE DRUG IN A MATRIX AND A SOLUBILITY-ENHANCING POLYMER | PFIZER PRODUCTS INC. (US) | 2003-01-03 | — | — | WO | disclosed |
| WO-2003000295-A2 | SELF-EMULSIFYING FORMULATIONS OF CHOLESTERYL ESTER TRANSFER PROTEIN INHIBITORS | PFIZER PRODUCTS INC. (US) | 2003-01-03 | — | — | WO | disclosed |
| WO-2003000292-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING LOW-SOLUBILITY AND/OR ACID-SENSITIVE DRUGS AND NEUTRALIZED ACIDIC POLYMERS | PFIZER PRODUCTS INC. (US) | 2003-01-03 | — | — | WO | disclosed |
| WO-2003000238-A1 | PHARMACEUTICAL COMPOSITIONS OF ADSORBATES OF AMORPHOUS DRUG | PFIZER PRODUCTS INC. (US) | 2003-01-03 | — | — | WO | disclosed |
| EP-1269994-A2 | Pharmaceutical compositions comprising drug and concentration-enhancing polymers | Pfizer Products Inc. (US) | 2003-01-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030191306-A1 | Substituted N-Aliphatic-N-Aromatictertiary-Heteroalkylamines useful for inhibiting cholesteryl ester transfer protein activity | CETP, DBI, MTTP | SLC6A2 993/4885SLC6A4 1073/4885CETP 1/4885 |
| US-20030054038-A1 | Pharmaceutical compositions of drugs and neutralized acidic polymers | PDE7A, CA6, PDE9A | SLC6A2 305/4885SLC6A4 536/4885CETP 1214/4885 |
| US-20010018446-A1 | Substituted N-Aliphatic-N-Aromatictertiary-Heteroalkylamines useful for inhibiting cholesteryl ester transfer protein activity | CETP, DBI, MTTP | SLC6A2 993/4885SLC6A4 1073/4885CETP 1/4885 |
| US-20030054037-A1 | Pharmaceutical compositions of adsorbates of amorphous drug | ABCG2, ALB, SLCO1A2 | SLC6A2 402/4885SLC6A4 668/4885CETP 162/4885 |
| US-20030022944-A1 | Self-emulsifying formulations of cholesteryl ester transfer protein inhibitors | CETP, LCAT, LIPA | SLC6A2 1540/4885SLC6A4 1544/4885CETP 1/4885 |
| US-20160374945-A1 | PHARMACEUTICAL COMPOSITIONS OF DISPERSIONS OF DRUG AND NEUTRAL POLYMERS | LIPA, ABCG2, ABCB11 | SLC6A2 935/4885SLC6A4 1516/4885CETP 227/4885 |
| US-20120295988-A1 | Pharmaceutical Compositions of Dispersions of Amorphous Drugs Mixed with Polymers | ABCG2, ABCB1, MATR3 | SLC6A2 1290/4885SLC6A4 1850/4885CETP 534/4885 |
| US-20140210117-A1 | PHARMACEUTICAL COMPOSITIONS OF DISPERSIONS OF DRUG AND NEUTRAL POLYMERS | LIPA, ABCG2, ABCB11 | SLC6A2 935/4885SLC6A4 1516/4885CETP 227/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.